Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:2043-2053
Published online before print August 11, 2005, doi: 10.1161/01.ATV.0000181762.31694.da
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
25/10/2043    most recent
01.ATV.0000181762.31694.dav1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Feinbloom, D.
Right arrow Articles by Bauer, K. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feinbloom, D.
Right arrow Articles by Bauer, K. A.
Related Collections
Right arrow Acute myocardial infarction
Right arrow Chronic ischemic heart disease
Right arrow Arterial thrombosis
Right arrow Coagulation and fibronolysis
Right arrow Thrombosis risk factors
Right arrow Endothelium/vascular type/nitric oxide
Right arrow Mechanism of atherosclerosis/growth factors
Right arrow Pathophysiology
Right arrow Risk Factors
Right arrow Acute Cerebral Infarction
Right arrow Acute Stroke Syndromes
Right arrow Other arteriosclerosis
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:2043.)
© 2005 American Heart Association, Inc.


Brief Reviews

Assessment of Hemostatic Risk Factors in Predicting Arterial Thrombotic Events

David Feinbloom; Kenneth A. Bauer

From the Department of Medicine, Beth Israel Deaconess Medical Center (D.F., K.A.B.), and VA Boston Healthcare System (K.A.B.), Harvard Medical School, Boston, Mass.

Correspondence to Kenneth A. Bauer, MD, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston, MA 02115. E-mail kbauer{at}bidmc.harvard.edu

Series Editor: William Haynes
ATVB In Focus Noninvasive Assessment of Atherosclerosis: From Structure to Function

Previous Brief Reviews in this Series:

•Choudhury RP, Fuster V, Badimon JJ. Fisher EA, Fayad ZA. MRI and characterization of atherosclerotic plaque: emerging applications and molecular imaging. 2002;22:1065–1074.
•Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. 2003;23:168–175.
•Oliver JJ, Webb DJ. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. 2003;23:554–566.
•Madjid M, Zarrabi A, Litovsky S, Willerson JT, Casscells W. Finding vulnerable atherosclerotic plaques: is it worth the effort? 2004;24:1775–1782.
•Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. 2005;25:279–286.

Arterial thrombosis results from endovascular injury and, to a lesser extent, alterations in hemostatic equilibrium. Although multiple hereditary and acquired hemostatic risk factors have been described in the pathophysiology of venous thrombosis, the degree and type of abnormalities that contribute to arterial thrombosis are less well understood. Endothelial cell injury with the elaboration of proinflammatory mediators stimulates the process of arterial thrombosis. Although this is most often the result of endovascular injury attributable to atherosclerotic disease, other disease states can elicit a similar response as well. Similarly, once thrombosis has been initiated, variations in the activity of coagulation proteins and endogenous anticoagulants, as well as the kinetics of platelet aggregation, may alter the effectiveness of thrombus formation. Epidemiological studies have identified several acquired or inherited states that may result in endothelial damage or altered hemostatic equilibrium, thereby predisposing patients to arterial thrombosis. These include hyperhomocysteinemia, elevated C-reactive protein, antiphospholipid antibodies, elevated fibrinogen, Factor VII, plasminogen activator inhibitor-1 (PAI-1), hereditary thrombophilias, and platelet hyper-reactivity. This review explores our present understanding of these risk factors in the development of arterial thrombotic events. At present, the literature supports a role for hyperhomocysteinemia, elevated C-reactive protein, and elevated fibrinogen as risk factors for arterial thrombosis. Similarly, the literature suggests that lupus anticoagulants and, to a lesser extent, elevated titers of cardiolipin IgG antibodies predispose to arterial vascular events. In certain subsets of patients, including those with concomitant cardiac risk factors, <55 years of age, and women, hereditary thrombophilias such as carriership of the factor V Leiden and the prothrombin G20210A mutations may confer a higher risk of arterial thrombosis. However, the data on Factor VII, PAI-1, and platelet receptor polymorphisms are contradictory or lacking.


Key Words: arterial • thrombosis • atherosclerosis • hemostasis • risk factors




This article has been cited by other articles:


Home page
J Child NeurolHome page
M. R. Golomb, M. Heiny, and B. P. Garg
Two Cousins With Neonatal Stroke, PAI-1 4G Variant and MTHFR A1298C Mutation
J Child Neurol, June 1, 2007; 22(6): 753 - 755.
[Abstract] [PDF]


Home page
BloodHome page
M. J. Maxwell, E. Westein, W. S. Nesbitt, S. Giuliano, S. M. Dopheide, and S. P. Jackson
Identification of a 2-stage platelet aggregation process mediating shear-dependent thrombus formation
Blood, January 15, 2007; 109(2): 566 - 576.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
C. Vlachopoulos, K. Aznaouridis, N. Ioakeimidis, K. Rokkas, C. Vasiliadou, N. Alexopoulos, E. Stefanadi, A. Askitis, and C. Stefanadis
Unfavourable endothelial and inflammatory state in erectile dysfunction patients with or without coronary artery disease
Eur. Heart J., November 2, 2006; 27(22): 2640 - 2648.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. L.G. Correia and W. G. Haynes
A Role for Plasminogen Activator Inhibitor-1 in Obesity: From Pie to PAI?
Arterioscler. Thromb. Vasc. Biol., October 1, 2006; 26(10): 2183 - 2185.
[Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
I. Lang and K. Kerr
Risk Factors for Chronic Thromboembolic Pulmonary Hypertension
Proceedings of the ATS, September 1, 2006; 3(7): 568 - 570.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
Y. M Pacheco, B. Bermudez, S. Lopez, R. Abia, J. Villar, and F. J. Muriana
Ratio of oleic to palmitic acid is a dietary determinant of thrombogenic and fibrinolytic factors during the postprandial state in men.
Am. J. Clinical Nutrition, August 1, 2006; 84(2): 342 - 349.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
D. Feinbloom and K. A. Bauer
The role of other hemostatic factors in predicting arterial thrombotic events.
Arterioscler. Thromb. Vasc. Biol., March 1, 2006; 26(3): e29 - e29.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
C. J. Boos and G. Y.H. Lip
Letter to the Editor: Assessment of Hemostatic Risk Factors in Predicting Arterial Thrombotic Events
Arterioscler. Thromb. Vasc. Biol., February 1, 2006; 26(2): e18 - e18.
[Full Text] [PDF]